Dual PPAR Agonist Applications in Metabolic Liver Disorders

Dual activation of peroxisome proliferator‐activated receptors α and γ offers a multifaceted approach to treating metabolic liver disorders by combining lipid‐lowering, anti‐inflammatory and insulin‐sensitising effects. PPARα stimulation enhances fatty acid oxidation and reduces hepatic triglyceride accumulation, while PPARγ activation improves insulin sensitivity and adipokine profiles. This dual mechanism addresses key drivers of non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), by attenuating steatosis, inflammation, oxidative stress and fibrogenesis. Preclinical studies have delineated transcriptomic and lipidomic shifts under dual PPAR modulation, corroborating reductions in lipotoxic intermediates and profibrotic signalling. Clinically, dual agonists have demonstrated improvements in biochemical markers and non-invasive imaging surrogates of liver injury, supporting their potential to fill a therapeutic gap in conditions where no approved pharmacological options currently exist.

Research from Nature Portfolio

Recent animal-model investigations report that treatment with a dual PPARα/γ agonist markedly reverses diet-induced NASH in mice. Outcomes include lower body weight, improved insulin resistance indices, reduced plasma alanine transaminase and aspartate transaminase, and restoration of antioxidant enzyme expression. Histological analyses show resolution of steatosis, lobular inflammation, hepatocellular ballooning and early fibrosis. Transcriptomic and lipidomic profiling reveal upregulation of canonical PPAR target genes alongside downregulation of inflammatory and unfolded protein response pathways. In parallel, a prospective observational study in patients with NAFLD and diabetic dyslipidaemia receiving the same dual agonist reported significant reductions in transaminases, liver stiffness measurement and controlled attenuation parameter over 24 weeks. Glycaemic control and lipid profiles also improved without serious adverse events. Furthermore, a randomised placebo‐controlled trial in individuals with type 2 diabetes and hypertriglyceridaemia demonstrated that dual agonist therapy significantly enhanced insulin sensitivity measured by hyperinsulinaemic-euglycaemic clamp, reduced triglyceride levels and elevated high-density lipoprotein cholesterol, reinforcing direct effects on glucose and lipid homeostasis.

Dual PPAR Agonist Applications in Metabolic Liver Disorders publication trend

The graph below shows the total number of articles in dual ppar agonist applications in metabolic liver disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Peroxisome Proliferator-Activated Receptors (PPARs): Nuclear receptors that regulate lipid metabolism, glucose homeostasis and inflammation when activated by specific ligands.

NAFLD: Non-alcoholic fatty liver disease, a spectrum of liver conditions characterised by excessive fat accumulation in hepatocytes without significant alcohol intake.

NASH: Non-alcoholic steatohepatitis, an advanced form of NAFLD marked by inflammation, hepatocyte injury and variable fibrosis.

Steatosis: Accumulation of triglycerides within hepatocytes, visible as fat droplets on histology.

Fibrosis: Excessive deposition of extracellular matrix proteins in the liver, leading to scar formation and functional impairment.

Insulin Resistance: A reduced cellular response to insulin, contributing to hyperglycaemia and dyslipidaemia.

Liver Stiffness Measurement (LSM): A non-invasive elastography metric reflecting the rigidity of liver tissue, used to estimate fibrosis stage.

References

1. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver International (2017).
2. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Scientific Reports (2020).
3. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Scientific Reports (2020).
4. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial. Scientific Reports (2019).
5. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. BMC Pharmacology and Toxicology (2021).
6. Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience. JGH Open (2023).